Somatropin (rDNA origin)
Phase 3Completed 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Turner Syndrome
Conditions
Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases, Dwarfism
Trial Timeline
Jun 1, 2004 → Jul 1, 2008
NCT ID
NCT00234533About Somatropin (rDNA origin)
Somatropin (rDNA origin) is a phase 3 stage product being developed by Ipsen for Turner Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT00234533. Target conditions include Turner Syndrome, Renal Insufficiency, Chronic, Pituitary Diseases.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00234533 | Phase 3 | Completed |
Competing Products
10 competing products in Turner Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Somatropin | Eli Lilly | Phase 3 | 77 |
| Humatrope | Eli Lilly | Approved | 85 |
| 17 beta estradiol | Eli Lilly | Phase 3 | 77 |
| Somatropin + Ethinyl estradiol + Medroxyprogesterone acetate | Eli Lilly | Phase 3 | 77 |
| r-hGH | Merck | Approved | 85 |
| Somapacitan + Norditropin® | Novo Nordisk | Phase 3 | 76 |
| estradiol | Novo Nordisk | Approved | 84 |
| Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch | Novo Nordisk | Phase 1 | 32 |
| somatotropin | Pfizer | Pre-clinical | 22 |
| Lonapegsomatropin + Somatropin | Ascendis Pharma | Phase 2 | 49 |